• DOI:10.1007/s12032-010-9700-3
Corpus ID: 207372333

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

@article{Coronel2011ADP,
  title={A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results},
  author={J. Coronel and L. Cetina and I. Pacheco and C. Trejo-Becerril and A. Gonz{\'a}lez-Fierro and E. De la Cruz-Hernandez and E. P{\'e}rez-C{\'a}rdenas and L. Taja-Chayeb and Daymi Arias-Bofill and M. Candelaria and S. Vidal and A. Duenas-Gonzalez},
  journal={Medical Oncology},
  year={2011},
  volume={28},
  pages={540-546}
}

J. Coronel, L. Cetina, +9 authors A. Duenas-Gonzalez

Published 2011

Medicine

Medical Oncology

The reversing of epigenetic aberrations using the inhibitors of DNA methylation and histone deacetylases may have therapeutic value in cervical cancer. This is a randomized phase III, placebo-controlled study of hydralazine and valproate (HV) added to cisplatin topotecan in advanced cervical cancer. Patients received hydralazine at 182 mg for rapid, or 83 mg for slow acetylators, and valproate at 30 mg/kg, beginning a week before chemotherapy and continued until disease progression. Response… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed